MusclePharm (MSLP) stock price, revenue, and financials

MusclePharm market cap is $18.1 m, and annual revenue was $102.16 m in FY 2017

$18.1 M

MSLP Mkt cap, 05-Oct-2018

$27.4 M

MusclePharm Revenue Q3, 2018
MusclePharm Gross profit (Q3, 2018)8.8 M
MusclePharm Gross profit margin (Q3, 2018), %32.1%
MusclePharm Net income (Q3, 2018)-2 M
MusclePharm EBIT (Q3, 2018)-991 K
MusclePharm Cash, 30-Sep-20181.7 M
MusclePharm EV17.8 M

MusclePharm Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

177.4m166.9m132.5m102.2m

Revenue growth, %

(6%)(21%)

Cost of goods sold

77.7m121.4m109.9m88.0m71.7m

Gross profit

56.0m56.9m44.5m30.4m

Gross profit Margin, %

32%34%34%30%

Sales and marketing expense

11.8m25.3m31.2m18.0m10.1m

R&D expense

1.1m4.0m4.3m1.9m642.0k

General and administrative expense

7.2m13.4m19.4m15.9m12.1m

Operating expense total

20.1m42.7m106.9m53.1m37.6m

EBIT

(14.3m)(19.4m)(49.9m)(8.7m)(7.2m)

EBIT margin, %

(11%)(30%)(7%)(7%)

Interest expense

783.3k

Interest income

1.4m

Pre tax profit

(13.8m)(51.8m)(3.2m)(10.8m)

Income tax expense

(115.5k)33.0k105.0k318.0k(108.0k)

Net Income

(17.7m)(13.8m)(51.9m)(3.5m)(11.0m)

MusclePharm Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.4m1.0m7.1m4.9m6.2m

Accounts Receivable

13.7m

Inventories

15.8m1.7m12.5m8.6m6.5m

Current Assets

44.5m46.4m47.3m28.8m30.5m

PP&E

7.8m6.7m3.2m1.8m

Total Assets

52.2m66.4m63.8m34.1m33.8m

Accounts Payable

28.4m27.8m39.7m9.6m11.7m

Current Liabilities

32.4m42.8m67.3m38.4m28.5m

Long-term debt

2.5m8.0m3.0m3.0m

Total Debt

2.5m3.0m3.0m

Total Liabilities

32.4m73.8m39.0m46.4m

Additional Paid-in Capital

103.1m129.1m147.6m156.3m159.6m

Retained Earnings

(81.8m)(95.7m)(147.5m)(151.0m)(162.0m)

Total Equity

19.7m23.4m(4.9m)(12.5m)

Financial Leverage

2.6 x2.8 x-7 x-2.7 x

Quarterly

USDQ2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

8.7m5.7m3.3m3.8m2.9m4.2m3.5m9.1m13.1m5.9m3.0m3.6m4.9m5.1m2.4m1.7m

Accounts Receivable

9.2m10.9m19.6m1.3m23.2m

Inventories

1.2m9.6m24.0m14.9m19.3m8.6m6.9m8.0m6.1m6.1m6.3m7.7m7.7m7.3m

Current Assets

21.7m34.4m49.0m50.5m59.0m53.2m45.2m45.2m44.8m32.9m26.6m25.6m26.3m30.8m27.5m26.4m

PP&E

7.6m7.0m6.4m3.9m3.3m2.9m2.5m2.2m1.6m1.5m576.0k

Total Assets

23.3m41.5m65.6m66.9m79.6m75.1m62.2m61.2m50.6m38.3m31.1m29.8m30.1m33.9m30.4m28.3m

Accounts Payable

8.2m16.5m24.3m23.9m28.1m37.8m40.4m39.4m39.1m36.1m10.9m9.1m9.4m14.9m16.6m20.7m

Short-term debt

45.6k45.6k

Current Liabilities

10.6m18.9m30.7m28.5m41.4m54.2m67.5m72.6m65.3m53.9m38.1m37.8m22.4m30.4m27.6m28.5m

Long-term debt

2.5m45.6k45.6k6.0m2.6m3.0m3.0m3.0m2.0m2.0m1.5m

Total Debt

2.5m91.2k91.2k6.0m2.6m3.0m3.0m3.0m2.0m2.0m1.5m

Total Liabilities

10.6m18.9m30.8m28.8m41.5m56.9m67.8m73.1m65.6m54.8m38.5m39.8m41.6m48.5m46.0m45.8m

Additional Paid-in Capital

87.1m101.0m115.4m118.3m125.0m138.6m142.5m152.4m153.5m153.6m156.9m157.4m158.0m159.8m159.9m160.0m

Retained Earnings

(73.9m)(77.8m)(79.1m)(78.7m)(79.4m)(110.2m)(137.8m)(154.1m)(158.3m)(159.8m)(154.1m)(157.3m)(159.4m)(164.3m)(165.3m)(167.3m)

Total Equity

34.8m38.1m38.1m18.2m(11.9m)(15.0m)(16.4m)(7.4m)(10.0m)(11.5m)(14.6m)(15.6m)(17.5m)

Debt to Equity Ratio

0 x-0.1 x-0.1 x-0.1 x

Debt to Assets Ratio

0 x0.1 x0.1 x0.1 x

Financial Leverage

1.9 x1.8 x2.1 x4.1 x-5.2 x-3.4 x-2.3 x-4.2 x-3 x-2.6 x-2.3 x-1.9 x-1.6 x

MusclePharm Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(17.7m)(13.8m)(51.9m)(3.5m)(11.0m)

Depreciation and Amortization

709.0k1.3m1.8m1.6m1.1m

Accounts Receivable

(10.7m)(2.6m)(5.6m)7.3m(4.6m)

Inventories

2.0k5.9m(480.0k)2.1m

Accounts Payable

23.1m14.2m(20.8m)2.0m

Cash From Operating Activities

(10.0m)(4.1m)5.5m(15.1m)(5.1m)

Purchases of PP&E

(1.9m)(4.1m)(1.5m)(508.0k)(37.0k)

Cash From Investing Activities

(3.5m)(1.6m)(3.0m)5.4m(37.0k)

Long-term Borrowings

(4.4m)(17.0k)

Cash From Financing Activities

18.9m1.4m3.7m7.5m6.4m

Interest Paid

411.4k158.0k527.0k1.6m2.4m

Income Taxes Paid

87.4k301.0k77.0k218.0k106.0k

MusclePharm Ratios

USDY, 2018

EV/EBIT

-18 x

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-1.6 x

MusclePharm Employee Rating

2.317 votes
Culture & Values
2.3
Work/Life Balance
2.4
Senior Management
2.1
Salary & Benefits
2.5
Career Opportunities
2.1
Source